Table 3 |
|||
|
Potential risk factors for the first major infection in 103 patients with SLE |
|||
| = 1 major infection (n = 23) |
No major infection (n = 80) |
p value |
|
|
|
|||
| Laboratory variables |
|||
| Functional MBL serum level, μg/mla |
1.60 (0.04–7.00) |
1.40 (0.04–7.60) |
0.316 |
| Functional MBL serum level <0.05 μg/ml |
2/23 (9%) |
11/80 (14%) |
0.522 |
| MBL-induced C4 deposition on mannan, percentagea |
64.8 (3.4–400) |
71.1 (1.1–400) |
0.550 |
| MBL-induced C4 deposition on mannan <10% |
5/23 (22%) |
16/80 (20%) |
0.856 |
| MBL pathway activity, percentagea |
14.1 (0.1–111) |
17.3 (0.1–119) |
0.806 |
| MBL pathway activity <10% |
10/23 (44%) |
34/80 (43%) |
0.934 |
| Clinical variables |
|||
| Disease duration at follow-up, years |
12.5 ± 7.4 |
5.1 ± 5.7 |
0.0001 |
| Previous SLE glomerulonephritis |
10/23 (44%) |
10/80 (10%) |
0.001 |
| Treatment variables |
Use <3 months before the first major infection |
Previous use ever since lupus diagnosis |
|
| Oral corticosteroids |
17/23 (74%) |
41/80 (51%) |
0.916 |
| Intravenous methylprednisolone |
5/23 (22%) |
9/80 (11%) |
0.204 |
| Hydroxychloroquine |
6/23 (26%) |
70/80 (88%) |
0.0001 |
| Methotrexate |
0/23 (0%) |
9/80 (11%) |
0.094 |
| Azathioprine |
8/23 (35%) |
21/80 (26%) |
0.424 |
| Oral cyclophosphamide |
1/23 (4%) |
1/80 (1%) |
0.373 |
| Intravenous cyclophosphamide |
4/23 (17%) |
4/80 (5%) |
0.065 |
|
|
|||
|
Except where indicated otherwise, values are presented as the mean ± standard deviation. aValues are presented as the median (range). MBL, mannose-binding lectin; SLE, systemic lupus erythematosus. |
|||
|
Bultink et al. Arthritis Research & Therapy 2006 8:R183 doi:10.1186/ar2095 |
|||
